Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions
- PMID: 34674005
- PMCID: PMC8528941
- DOI: 10.1007/s00415-021-10848-4
Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions
Abstract
Acute and post-acute neurological symptoms, signs and diagnoses have been documented in an increasing number of patients infected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes Coronavirus Disease 2019 (COVID-19). In this review, we aimed to summarize the current literature addressing neurological events following SARS-CoV-2 infection, discuss limitations in the existing literature and suggest future directions that would strengthen our understanding of the neurological sequelae of COVID-19. The presence of neurological manifestations (symptoms, signs or diagnoses) both at the onset or during SARS-CoV-2 infection is associated with a more severe disease, as demonstrated by a longer hospital stay, higher in-hospital death rate or the continued presence of sequelae at discharge. Although biological mechanisms have been postulated for these findings, evidence-based data are still lacking to clearly define the incidence, range of characteristics and outcomes of these manifestations, particularly in non-hospitalized patients. In addition, data from low- and middle-income countries are scarce, leading to uncertainties in the measure of neurological findings of COVID-19, with reference to geography, ethnicity, socio-cultural settings, and health care arrangements. As a consequence, at present a specific phenotype that would specify a post-COVID (or long-COVID) neurological syndrome has not yet been identified.
Keywords: COVID-19; Neurological diseases; Post-COVID; SARS-CoV-2.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Conflict of interest statement
Dr. Beghi reports grants from the Italian Ministry of Health, grants from SOBI, personal fees from Arvelle Therapeutics, grants from American ALS Association, outside the submitted work. Dr. Allegri reports grants from Fleni Neurological Institute (Buenos Aires, Argentina), grants from CONICET (National Council of Scientific and Technological Research), Argentina, grants from Washington University, Subcontract NIH (USA), grants from Alzheimer Association (USA), outside the submitted work. Dr. Garcia-Azorin reports grants from International Headache Society, personal fees from the World Health Organization, personal fees from Lilly, personal fees from Teva, personal fees from Novartis, personal fees from Allergan, personal fees from Chiesi, grants from the Spanish Society of Neurology, grants from Fundacion Estudios de Ciencias de la Salud de Castilla y Leòn, grants from Colegio de Medicos de Valladolid, outside the submitted work. Dr. Frontera reports grants from NIH/NINDS and NIH/NIA for COVID-related research. Dr. Winkler and Dr. Westenberg report grants from School of Medicine of the Technical University of Munich, outside the submitted work. Dr. Guekht report a grant from the Russian Scientific Foundation, outside of the submitted work.All the other authors have nothing to declare.
References
-
- Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.Erratum.In:BMJ2020;368:m1295. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
